Family History Shapes Psoriatic Disease Onset in PsA

Family History Shapes Psoriatic Disease Onset in PsA

Patients with psoriatic arthritis with a family history of psoriatic disease are diagnosed with psoriasis and psoriatic arthritis earlier than those without such history.

Johnson & Johnson Seeks FDA Approval for First Oral IL‑23 Inhibitor to Treat Plaque Psoriasis

SPRING HOUSE, PA — Johnson & Johnson has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for icotrokinra, a once-daily oral peptide therapy targeting the …

Personalizing Psoriasis Care Across Varying Patient Profiles

Tildrakizumab, HCP-administered biologics, and lifestyle-based decision-making took center stage in an interactive discussion led by Omar Noor, MD, FAAD, and colleagues.

Johnson & Johnson seeks FDA approval for icotrokinra

Johnson & Johnson has submitted a NDA seeking approval from the FDA for icotrokinra to treat moderate to severe plaque psoriasis (PsO).

J&J submits icotrokinra NDA for plaque psoriasis in patients 12 years and up

J&J is seeking the first approval for the investigational targeted oral peptide to treat patients 12 years and up with moderate-to-severe plaque psoriasis.